Profile data is unavailable for this security.
About the company
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
- Revenue in USD (TTM)114.70k
- Net income in USD-21.37m
- Incorporated2020
- Employees63.00
- LocationSAB Biotherapeutics Inc777 W 41St St, Suite 401MIAMI BEACH 33140United StatesUSA
- Phone+1 (305) 845-2813
- Fax+1 (302) 636-5454
- Websitehttps://www.sab.bio/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galectin Therapeutics Inc | 0.00 | -37.44m | 177.94m | 15.00 | -- | -- | -- | -- | -0.5913 | -0.5913 | 0.00 | -1.92 | 0.00 | -- | -- | 0.00 | -178.33 | -117.54 | -- | -197.34 | -- | -- | -- | -- | -- | -3.57 | -- | -- | -- | -- | -5.35 | -- | -- | -- |
| Kalaris Therapeutics Inc | 0.00 | -51.71m | 180.29m | 6.00 | -- | 4.31 | -- | -- | -87.38 | -87.38 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -50.77 | -52.59 | -52.70 | -57.65 | -- | -- | -- | -- | -- | -- | 0.4338 | -- | -- | -- | 69.14 | -- | -- | -- |
| Sol Gel Technologies Ltd | 18.97m | -8.99m | 184.14m | 34.00 | -- | 7.07 | -- | 9.71 | -3.23 | -3.23 | 6.81 | 9.34 | 0.4891 | -- | 2.25 | 557,941.20 | -23.17 | -29.32 | -27.70 | -33.19 | -- | -- | -47.37 | -138.22 | -- | -- | 0.00 | -- | 642.47 | -12.81 | 61.16 | -- | -68.01 | -- |
| Humacyte Inc | 1.57m | -36.97m | 194.93m | 218.00 | -- | -- | -- | 124.08 | -0.2206 | -0.2206 | 0.011 | -0.0299 | 0.0152 | -- | -- | 7,206.42 | -35.84 | -41.46 | -46.28 | -45.37 | 60.53 | -- | -2,353.22 | -8,438.13 | 0.8965 | -- | 1.10 | -- | -- | -- | -34.24 | -- | -28.00 | -- |
| SAB Biotherapeutics Inc | 114.70k | -21.37m | 199.00m | 63.00 | -- | 1.20 | 9.05 | 1,734.93 | -2.81 | -2.81 | 0.0043 | 3.48 | 0.001 | -- | 0.3492 | 1,820.64 | 15.80 | -- | 17.22 | -- | -- | -- | 16,338.04 | -- | -- | -- | 0.0197 | -- | -40.94 | -- | 19.17 | -- | -- | -- |
| Voyager Therapeutics Inc | 31.32m | -126.78m | 202.94m | 172.00 | -- | 0.9212 | -- | 6.48 | -2.17 | -2.17 | 0.5358 | 3.96 | 0.0877 | -- | 2.64 | 182,069.80 | -35.50 | -1.01 | -39.95 | -1.27 | -- | -- | -404.85 | -2.34 | -- | -- | 0.00 | -- | -68.00 | -5.18 | -149.12 | -- | -14.53 | -- |
| Silence Therapeutics plc | 25.81m | -65.01m | 204.52m | 115.00 | -- | 3.06 | -- | 7.92 | -0.462 | -0.462 | 0.1831 | 0.5227 | 0.1383 | -- | 124.98 | -- | -34.83 | -39.00 | -39.01 | -48.09 | 91.20 | 55.91 | -251.86 | -203.50 | -- | -- | 0.00 | -- | 36.71 | 168.26 | 16.45 | -- | 78.99 | -- |
| Inhibikase Therapeutics Inc | 0.00 | -47.66m | 206.74m | 15.00 | -- | 1.75 | -- | -- | -1.15 | -1.15 | 0.00 | 0.9745 | 0.00 | -- | -- | 0.00 | -113.51 | -56.32 | -131.71 | -65.21 | -- | -- | -- | -1,965.97 | -- | -- | 0.00 | -- | -100.00 | -- | -44.62 | -- | -- | -- |
| Ovid Therapeutics Inc | 6.61m | -36.33m | 206.99m | 23.00 | -- | 2.53 | -- | 31.32 | -0.5112 | -0.5112 | 0.093 | 0.6282 | 0.0794 | -- | -- | 287,391.30 | -43.64 | -13.89 | -49.07 | -15.44 | -- | -- | -549.62 | -40.79 | -- | -- | 0.00 | -- | 44.50 | -- | 49.50 | -- | -7.98 | -- |
| Neonc Technologies Holdings Inc | 59.99k | -48.88m | 209.35m | 3.00 | -- | -- | -- | 3,489.73 | -2.59 | -2.59 | 0.0032 | -0.6067 | 0.0176 | -- | -- | -- | -1,431.87 | -- | -- | -- | 33.34 | -- | -81,472.06 | -- | -- | -22.45 | -- | -- | 17.80 | -- | 20.26 | -- | -- | -- |
| Alector Inc | 69.05m | -107.74m | 209.57m | 156.00 | -- | 3.57 | -- | 3.04 | -1.07 | -1.07 | 0.6893 | 0.5371 | 0.1622 | -- | -- | 290,117.70 | -25.31 | -19.30 | -34.27 | -23.57 | -- | -- | -156.03 | -108.92 | -- | -- | 0.1428 | -- | 3.60 | 36.50 | 8.70 | -- | -39.33 | -- |
| Arcturus Therapeutics Holdings Inc | 97.60m | -66.71m | 210.25m | 174.00 | -- | 0.8975 | -- | 2.15 | -2.46 | -2.46 | 3.60 | 8.25 | 0.2989 | -- | 5.12 | 560,919.60 | -20.43 | -19.22 | -24.18 | -24.16 | -- | -- | -68.35 | -68.95 | -- | -- | 0.00 | -- | -8.69 | 48.93 | -172.30 | -- | -4.55 | -- |
| Surrozen Inc | 3.60m | -86.91m | 210.86m | 40.00 | -- | -- | -- | 58.51 | -19.76 | -19.76 | 0.6008 | -2.74 | 0.0507 | -- | 0.4882 | 90,100.00 | -122.36 | -60.48 | -134.33 | -68.26 | -- | -- | -2,411.38 | -993.19 | -- | -- | -- | -- | -- | -- | -47.68 | -- | -55.92 | -- |
| Heron Therapeutics Inc | 155.10m | -13.58m | 214.53m | 122.00 | -- | 30.54 | -- | 1.38 | -0.0809 | -0.0809 | 0.9199 | 0.0812 | 0.6604 | 0.6977 | 2.09 | 1,271,287.00 | -5.78 | -50.09 | -9.22 | -70.09 | 73.92 | 56.53 | -8.75 | -136.13 | 1.78 | -- | 0.9037 | -- | 13.57 | -0.2317 | 87.72 | -- | -24.93 | -- |
Data as of Feb 12 2026. Currency figures normalised to SAB Biotherapeutics Inc's reporting currency: US Dollar USD
44.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Commodore Capital LPas of 30 Sep 2025 | 4.40m | 9.25% |
| RA Capital Management LPas of 30 Sep 2025 | 4.40m | 9.25% |
| Perceptive Advisors LLCas of 14 Jan 2026 | 3.47m | 7.29% |
| Woodline Partners LPas of 30 Sep 2025 | 2.85m | 5.99% |
| Sessa Capital IM LPas of 30 Sep 2025 | 2.20m | 4.62% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.77m | 3.72% |
| BVF Partners LPas of 30 Sep 2025 | 932.70k | 1.96% |
| Sphera Funds Management Ltd.as of 30 Sep 2025 | 566.40k | 1.19% |
| HB Wealth Management LLC (GA)as of 31 Dec 2025 | 307.50k | 0.65% |
| AWM Investment Co., Inc.as of 30 Sep 2025 | 200.00k | 0.42% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
